RecruitingRecruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814 · Whitehawk Therapeutics, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors
About this study
The study consists of 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, participants with non-squamous Endothelial Growth Factor Receptor Wild type (EGFR Wt) NSCLC, platinum resistant ovarian cancer (PROC), and endometrial cancer will be enrolled. In Phase 1b, up to four expansion cohorts will be opened based on the safety, tolerability, PK, and preliminary antitumor data in Phase 1a. Expansion Cohort 1 will evaluate non-squamous EGFR WT NSCLC, and Expansion Cohort 2 will evaluate endometrial cancer.
In Phase 1a of the study, HWK-007 will initially be administered as an intravenous (IV) infusion every 3 weeks (Q3W).
Eligibility criteria
Inclusion Criteria:
Have one of the following solid tumor cancers:
1. Monotherapy escalation and backfill cohorts:
1. non-squamous EGFR-Wt NSCLC
2. Endometrial carcinoma
3. Platinum Resistant Ovarian Cancer
2. Monotherapy expansion cohorts:
a. Non-squamous EGFR-Wt NSCLC b. Endometrial Carcinoma b. Additional tumor indications to be defined in a future amendment
Exclusion Criteria:
1. Current requirement for parenteral nutrition.
2. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.
3. Any serious unresolved toxicities from prior therapy
4. Significant cardiovascular disease
5. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
6. History of pneumonitis/interstitial lung disease
7. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Study design
Enrollment target: 226 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-12-19
Estimated completion: 2028-12
Last updated: 2026-11-20
Interventions
Drug: HWK-007
Primary outcomes
- • Determine Maximum Tolerated Dose (MTD) (From Cycle 1, Day 1 until Cycle 1, Day 21 (21-day cycles))
- • Determine Maximum Administered Dose (MAD) (From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles))
- • Determine the Recommended Dose for Expansion (RDE) (From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until MTD or MAD is identified.)
Sponsor
Whitehawk Therapeutics, Inc. · industry
Contacts & investigators
ContactClinical Trial Manager Lead · contact · WHWK-Clinical-Trials@whitehawktx.com · 866-742-9495
ContactCentral email mailbox - Whitehawk Therapeutics · contact · WHWK-Clinical-Trials@whitehawktx.com
InvestigatorDhiren Patel, MD · study_director, Whitehawk Therapeutics
InvestigatorJonathan Wahl · study_director, Whitehawk Therapeutics
All locations (17)
University of AlabamaRecruiting
Birmingham, Alabama, United States
University of Arizona Cancer CenterRecruiting
Tucson, Arizona, United States
University of ArkansasRecruiting
Little Rock, Arkansas, United States
UCLA - Hematology/Oncology Clinical Research UnitRecruiting
Los Angeles, California, United States
Stanford Cancer Institute, Stanford UniversityRecruiting
Palo Alto, California, United States
St. Francis Medical Center (OSF Healthcare)Recruiting
Peoria, Illinois, United States
University of MarylandRecruiting
Baltimore, Maryland, United States
START - MidwestRecruiting
Grand Rapids, Michigan, United States
Hackensack University Medical Center - John Theurer Cancer CenterRecruiting
Hackensack, New Jersey, United States
Roswell Park Comprehensive Care CenterRecruiting
Buffalo, New York, United States
University Hospital - Cleveland Medical CenterRecruiting
Cleveland, Ohio, United States
NEXT Oncology - AustinRecruiting
Austin, Texas, United States
NEXT - Oncology - HoustonRecruiting
Houston, Texas, United States
START - San AntonioRecruiting
San Antonio, Texas, United States
NEXT Oncology - Virginia Cancer SpecialistsRecruiting
Fairfax, Virginia, United States
Fred Hutchinson Cancer CenterRecruiting
Seattle, Washington, United States
Medical College of WisconsinRecruiting
Milwaukee, Wisconsin, United States